AstraZeneca Shares Plunge 16 Percent as Lung Cancer Study Fails – New York Times
City A.M. |
AstraZeneca Shares Plunge 16 Percent as Lung Cancer Study Fails
New York Times LONDON — AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday. The so-called MYSTIC study was the most anticipated … Shares in pharma giant AstraZeneca plunge more than 15% after lung cancer drug trial setback AstraZeneca Shares Crash the Most on Record After Key Cancer Drug Fails Astra plunges as vital cancer drug fails trial |
